Literature DB >> 31773344

State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications.

Veronica Azemawah1,2, Mohammad Reza Movahed1,3, Patrick Centuori1,2, Ryan Penaflor1,2, Pascal L Riel1,2, Steven Situ1,2, Mehrdad Shadmehr1, Mehrnoosh Hashemzadeh4,5.   

Abstract

Statins are currently the primary treatment for hyperlipidemia, particularly for the treatment of high levels of low-density lipoprotein cholesterol (LDL-C), as many studies have proven benefit in a variety of populations. The benefits of statin treatment for high cholesterol have been proven in many trials. Forefront among different adverse events is statin-induced myopathy, which still eludes complete understanding, and may range anywhere from muscle soreness or fatigue to potentially extremely rare occurrence of rhabdomyolysis.As most adverse events are rare and not life-threatening, in high-risk patients, a high-dose statin should be started initially as data suggests that clinicians rarely up titrate statin therapy after initial prescription leading to under-treatment of many patients requiring high-dose statin therapy. As we will discuss in this paper, musculoskeletal side effects are the main concern and reason for discontinuing statin therapy. The occurrence and true association of other adverse events in patients on statin such as new onset of diabetes, hepatic toxicity, or cognitive impairment are rare, controversial, and not proven. In placebo-controlled studies, abnormal liver function occurs to a similar degree in statin- and placebo-treated patients. This led to FDA removal of the requirement to monitor liver function tests in patients on statin therapy.The combination of statins with other compounds such as ezetimibe or PCSK9 inhibitors has shown some additional benefits in the treatment of hypercholesterolemia. The goal of this manuscript is to conduct a comprehensive review about most commonly used statins and compare data on their history, structures, benefits, adverse effects, and clinical outcomes.

Entities:  

Keywords:  Atherosclerosis; Cholesterol; Hypercholesterolemia; Hyperlipidemia; Low-density lipoprotein-cholesterol (LDL-C); PCSK9 inhibitors; Rhabdomyolysis; Statins

Mesh:

Substances:

Year:  2019        PMID: 31773344     DOI: 10.1007/s10557-019-06904-x

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  7 in total

1.  Lack of Awareness of Own Hypercholesterolemia or Statin Medication among Adult Statin Users in the United States: Prevalence and Patient Characteristics in a Repeated Cross-Sectional Study.

Authors:  Kenjiro Imai; Takehiro Sugiyama; Mitsuru Ohsugi; Masafumi Kakei; Kazuo Hara
Journal:  Int J Environ Res Public Health       Date:  2022-05-17       Impact factor: 4.614

2.  Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia.

Authors:  Neus Gimenez; Rupal Tripathi; Ariadna Giró; Laia Rosich; Mònica López-Guerra; Irene López-Oreja; Heribert Playa-Albinyana; Fabian Arenas; José Manuel Mas; Patricia Pérez-Galán; Julio Delgado; Elias Campo; Judith Farrés; Dolors Colomer
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

Review 3.  Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets.

Authors:  Maria Chiara Proto; Donatella Fiore; Chiara Piscopo; Cristina Pagano; Mario Galgani; Sara Bruzzaniti; Chiara Laezza; Patrizia Gazzerro; Maurizio Bifulco
Journal:  Prog Lipid Res       Date:  2021-04-26       Impact factor: 16.195

4.  7-Acetoxyhorminone from Salvia multicaulis Vahl. as Promising Inhibitor of 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase.

Authors:  Serkan Yigitkan; Abdulselam Ertas; Ramin Ekhteiari Salmas; Mehmet Firat; Ilkay Erdogan Orhan
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-04

Review 5.  Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.

Authors:  Nada Božina; Majda Vrkić Kirhmajer; Livija Šimičević; Lana Ganoci; Nikica Mirošević Skvrce; Iva Klarica Domjanović; Iveta Merćep
Journal:  Croat Med J       Date:  2020-04-30       Impact factor: 1.351

6.  Evaluating the performance of temporal pattern discovery: new application using statins and rhabdomyolysis in OMOP databases.

Authors:  M Lavallee; T Yu; L Evans; M Van Hemelrijck; C Bosco; A Golozar; A Asiimwe
Journal:  BMC Med Inform Decis Mak       Date:  2022-02-03       Impact factor: 2.796

7.  Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone.

Authors:  Tianhong Pan; Song-Chang Lin; Yu-Chen Lee; Guoyu Yu; Jian H Song; Jing Pan; Mark Titus; Robert L Satcher; Theocharis Panaretakis; Christopher Logothetis; Li-Yuan Yu-Lee; Sue-Hwa Lin
Journal:  Oncogene       Date:  2021-06-14       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.